Why is launching a drug in Europe different from launching in the US?

Access decades of experience

Regulatory Structure Insights

Key differences between FDA's unified approach and Europe's multiple authorization pathways.

Multi-country Considerations

Why harmonization challenges across 27 EU nations require different strategic thinking.

Review Process Understanding

How EMA's unique "clock-stop" review cycles affect your preparation and timeline
planning.

Post-Approval Realities

Critical differences between US and EU market access that impact your commercialization planning.